Docoh
Loading...

AMRX Amneal Pharmaceuticals

Filed: 10 May 21, 4:24pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2021

 

 

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-38485 32-0546926

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A Common Stock, par value $0.01 per share  AMRX  New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07

Submission of Matters to a Vote of Security Holders.

The Company held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) on May 5, 2021. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:

Proposal 1: To elect the following director nominees to hold office until the 2022 Annual Meeting of Stockholders and until their respective successors are elected and qualified:

 

   For   Against   Abstain   Broker Non-
Votes
 

Emily Peterson Alva

   231,387,113    3,503,246    24,437    18,156,126 

J. Kevin Buchi

   196,515,957    35,282,932    3,115,907    18,156,126 

Jeff George

   202,051,430    29,805,650    3,057,716    18,156,126 

John Kiely

   195,800,930    36,058,602    3,055,264    18,156,126 

Paul Meister

   206,606,442    25,255,223    3,053,131    18,156,126 

Ted Nark

   211,039,400    20,820,472    3,054,924    18,156,126 

Chintu Patel

   234,218,682    658,505    37,609    18,156,126 

Chirag Patel

   234,094,799    787,783    32,214    18,156,126 

Gautam Patel

   231,217,092    3,586,717    110,987    18,156,126 

Shlomo Yanai

   234,425,336    450,144    39,316    18,156,126 


Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:

 

For

 

Against

 

Abstain

 

Broker Non-

Votes

233,858,559

 881,197 175,040 18,156,126

Proposal 3: Approve an amendment to and restatement of the Amneal Pharmaceuticals, Inc. Certificate of Incorporation to remove references to the Company’s former Class B-1 common stock;

 

For

 

Against

 

Abstain

 

Broker Non-

Votes

252,305,563

 248,527 516,832 0

Proposal 4: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021:

 

For

 

Against

 

Abstain

 

Broker Non-

Votes

252,745,819

 269,437 55,666 0


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 10, 2021  AMNEAL PHARMACEUTICALS, INC.
  By: 

/s/ Stephen J. Manzano

  Name: Stephen J. Manzano
  Title: Senior Vice President, General Counsel and Corporate Secretary